The Symptom Diary Problem
Here's something that happens all the time in gastroenterology appointments: A doctor tells their IBD patient to "keep a symptom diary." The patient nods, downloads an app or grabs a notebook, and starts writing things down. Three months later at the follow-up, the doctor asks about symptoms and the patient pulls out their notes. The doctor looks at them for a moment, nods politely, and... doesn't really use any of it.
Aidy is working in this exact space, and the core insight is solid: people with chronic conditions like IBD need to track symptoms, but most tracking tools miss the mark on what matters clinically. The gap isn't about getting people to track more — it's about tracking the right things in a way doctors can actually use.
The interesting part? There's clinical validation for structured tracking. Studies show it reduces hospital admissions by 14% and improves quality-of-care scores from 50% to 84%. But here's the catch: those outcomes depend on tracking specific data points that align with clinical assessment tools like the Partial Mayo score. That means stool frequency, rectal bleeding amount, urgency episodes, pain intensity — not just "had a bad day" or "stomach hurt."
The opportunity for Aidy is making this structure invisible to users. Nobody wants to feel like they're filling out a medical form every morning. But with the right prompts, visual aids like the Bristol Stool Scale, and quick explanations of why each metric matters, tracking becomes both low-friction and clinically useful. The goal is data that a GI doctor can look at and immediately know whether to adjust treatment.
The Symptoms Nobody Talks About
Here's something that surprised me in the research: 83-100% of UC patients experience fatigue during active disease, yet it's the most underaddressed symptom in IBD care. Patients don't mention it because it doesn't seem relevant to bowel disease. Same with fever, weight loss, back pain, sleep disruption. These feel like separate problems.
But they're not. Systemic symptoms are often early warning signals for inflammation. The challenge is that patients don't connect the dots — they think IBD is about digestive issues, full stop. So they don't report fatigue to their GI team, and doctors don't have the full picture of disease activity.
For Aidy, there's a clear path here: expand symptom tracking beyond GI symptoms and include brief educational context. When someone logs their energy level, show them a one-line explanation about how inflammation affects energy production. When they track sleep disruption, mention the connection to nocturnal symptoms. This isn't about overwhelming users with information — it's about making the invisible connections visible, so people understand why their doctor cares about more than just bathroom trips.
The Silent Inflammation Challenge
This is the tricky part for any symptom tracking app: feeling good doesn't always mean being well. Only about 50% of patients who feel fine actually have their disease under control at the tissue level. Up to 54% have ongoing inflammation despite zero symptoms. And patients with elevated inflammatory markers but no symptoms? They have a 53-83% chance of relapsing within a few months.
This creates a retention problem. When people feel better, they stop engaging with health apps. Why track symptoms when you don't have any? But that's exactly when monitoring matters most, because subclinical inflammation is quietly causing long-term damage.
The solution isn't nagging people to log symptoms they don't have. It's showing them objective measures of disease activity — fecal calprotectin, CRP, other biomarkers — alongside their symptom scores. Build a dashboard that visualizes when these diverge, with plain language explanations of what it means. Help people understand that "treat-to-target" means aiming for biological remission, not just feeling okay.
This keeps users engaged during asymptomatic periods because they can see their disease activity independent of how they feel. It's also where the real clinical value lives: catching inflammation early, before it requires hospitalization.
We used Mimir to pull this analysis together from 14 sources about IBD management, patient behavior, and clinical guidelines. The full teardown has more detail on trigger identification, educational content strategy, and medication interaction guidance. What stands out is how much potential there is for apps like Aidy to close the gap between patient experience and clinical decision-making — not by doing more, but by doing the right things with real precision.